"The U.S. Food and Drug Administration today approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with skin infections.
Orbactiv is approved to treat patients with acute bacterial skin and skin structure infections (ABSS"...
The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:
Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
In controlled clinical studies the incidence of adverse reactions was low (0.2%) for Topicort® (desoximetasone) Ointment USP, 0.05% and included mild burning sensation at the site of application.
Read the Topicort (desoximetasone) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 6/14/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Topicort Information
Report Problems to the Food and Drug Administration
Find out what women really need.